Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 HKD | -3.31% | -8.59% | -19.86% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.86% | 157M | |
-2.31% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-19.06% | 7.32B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial